medigraphic.com
ISSN 2007-6509 (Print)
Órgano oficial de la Asociación Mexicana de Medicina Transfusional A.C.

2008, Number 1

<< Back Next >>

Rev Mex Med Transfus 2008; 1 (1)

Transfusion alternatives

Rodríguez MH

Language: Spanish
References: 22
Page: 31-36
PDF size: 116.73 Kb.


ABSTRACT

Identification of virus transfusion transmited (as HIV) and fear of been contaminated, sometimes alloimmunization and other clinical situations interfering with the selection of compatible blood, has been factors to the development of transfusion alternatives. In critical patients, hypovolemia, clinical troubles, can raise hypoxic severe anemia or bleeding tendency. Alternative procedures as crystalloid and colloid solutions can be helpfull as emergency resuscitation measures in hypovolemic patients. Allogenic red cell transfusion, is always mandatory according with clinical conditions. Other transfusion alternatives as autologous blood transfusion, has never represented more than 5% of transfused blood. Preoperative hemodilution, postoperative salvage blood, procoagulant drugs and erythropoietin are other alternatives used in order to reduce allogenic blood transfusion. blood sustitutes (oxigen carriers) as fluorocarbons and hemoglobin solutions (human or bovine) are still in experimental fase. Human recombinant erythropoietin is an effective alternative in renal insufficiency anemia, avoiding allogenic transfusion. Finally there are factor VIII and VIIa recombinants nucleic acid products, usefull in hemophilia.


REFERENCES

  1. Moulton JNY, Hardy X. Central venous pressure and its effects on blood loss during liver resection.

  2. Harvey GK, Anstee DJ. Mollison ´s blood transfusion in clinical medicine. Eleventh Edition Blackwell Publishing 2005 UK.

  3. James M. Volume expanders: Crystalloids vs Plasma colloids vs Synthetic colloids. ISBT Science Series (2006) 1, 52-58. XXIXth Congress of the ISBT, September 2006 Cape Town, South Africa.

  4. Strauss PG. All Formulations of Hydroxyethyl Starch are not the same. Letters to the editor. Transfusion 2007; 47: 1329-1330.

  5. Segal JB, Guallar E, Powe NR. Autologous blood transfusion in the United States: clinical and non clinical determinants of use. Trasnfusion 2001; 41: 1539-1547.

  6. Brecher ME. The rise and fall of preoperative autologous blood donation. Transfusion 2001; 41: 1459-1462.

  7. Cresswell SC, Wells AW, Whitehead and Seara B. Preoperative autologous deposit – why does it go wrong? XXI Annual Scientific Meeting British Blood Transfusion Society. Manchester UK. 2-5 October 2003. Transfusion Medicine 2003; 13: 45- P73.

  8. García-Erce JA, Muñoz-Gómez M, Cuenca-Esprérrez J, Leal-Navas SR, Giralt-Raichs M. Autologous blood donation in Spain (1994-2004). Abstracts of the XVIIth Regional Congress of the ISBT, Europe. June 23-27, 2007. Madrid Spain. Vox Sanguinis 2007; 93, Suppl 1: 226 (P 453).

  9. Shander A, Ryhwani TS. Acute normovolemic hemodilution. Transfusion 2004; 44: December Suppl 26S.

  10. Munen AFCM, Knoors NT, van Os J, Vesburg AD, Pilot P. Retransfusion of filtered shed blood in primary total hip and knee arthroplasty a prospective randomized clinical trial. Transfusion 2007; 47: 397-384.

  11. Waters JH, Dyga RM. Postoperative blood salvage outside the controlled world of the blood bank. Transfusion 2007; 47: 362-365.

  12. Hansen E, Pawlik M. Reasons against the retransfusion of unwashed wound blood. Transfusion 2004; 44: 45S-53S.

  13. Levy JH. Hemostatic agents. Transfusion 2004; 44: 58S-62S.

  14. Ickx BE, van der Linden PJ, Melot C, Wijns W, de Pauw L, Vandestat J, Hut F, Pradier O. Comparison of the effects of aprotinin and tranexamic acid on blood loss and red blood cell transfusion requirements during the late stages of liver transplantation. Transfusion 2006; 46: 595-605.

  15. Laird J. Erythropoietin: can we afford to use it? can we afford not to? Transfusion Medicine 2006; 16: 204-205.

  16. Fox SP, Pacey EP, Das-Gupta EP, Russell NH, Byrne JL. Low dose erythropoietin is effective in reducing transfusion requirements following allogenic HSCT. Transfusion Medicine 2005; 15: 475-480.

  17. FDA Information for Healthcare Professionals. Erythropoiesis Stimulant Agents (ESA). FDA Alert (11/16/2006), Updated 2/16/2007 and 3/09/2007.

  18. García-Erce JA, Cuenca J, Muñoz M, Izuel M, Martinez AA, Herrera A et al. Perioperative stimulation of erythropoiesis with intravenous iron and erythropoietin reduces transfusion requirements in patients with hip fracture. A prospective observational study. Vox Sanguinis 2005; 88: 235-243.

  19. Winslow RM. Current status of oxigen carriers (blood substitutes) Vox Sanguuinis 2006; 91: 102-110.

  20. O´Connel KA, Wood JJ, Wise RP et al. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA 2006; 295: 293-298.

  21. Kinoshita Y, Udagawua H, Tsutiami K, Useno M, Nakamura T, Isaka T et al. Bacteriological study of autologous cryoprecipitate derived fibrin glue as operative sealant. Trasnfusion Medicine 2004; 15: 429-433.

  22. Hébert PC, Wells G, Blajchman MA, Marshall J, Martín C, Pagliarello G et al. A multicenter randomized, controlled clinical trial of transfusion requirement in critical care. New Engl J Med 1999; 340: 409-417.




2020     |     www.medigraphic.com